ArticleJournal of perinatology : official journal of the California Perinatal Association2009
The relationship of serum AGE levels in diabetic mothers with adverse fetal outcome.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The relationship between advanced glycation end products and gestational diabetes: A systematic review and meta-analysis.PloS one · 2020Pooled it
- Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial.Scientific reports · 2018Trial
- Dysfunctional protection against advanced glycation due to thiamine metabolism abnormalities in gestational diabetes.Glycoconjugate journal · 2016Trial
- Low molecular weight heparin (nadroparin) improves placental permeability in rats with gestational diabetes mellitus via reduction of tight junction factors.Molecular medicine reports · 2020Article
- Influence of gestational diabetes on the activity of δ-aminolevulinate dehydratase and oxidative stress biomarkers.Redox report : communications in free radical research · 2018Article
- Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle.The Biochemical journal · 2016Review
- Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients.Archives of endocrinology and metabolismArticle
- Skin autofluorescence may be a biomarker associated suboptimal glycemic control in pregnant women with gestational diabetes mellitus.Diabetes & vascular disease researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate changes in serum-advanced glycosylation end product (AGE) levels in gestation diabetic mothers (GDMs) and its relationship with adverse fetal outcome. STUDY
designA total of 60 GDMs in mid-gestation and 72 late-gestation GDMs fulfilling the inclusion criteria were recruited. Seventy-two mid-gestation and 80 late-gestation mothers with no pregnancy complications acted as controls. Fasting blood glucose and serum AGE levels were analyzed in each group. Clinical data on these women and their perinatal outcomes were collected. Maternal serum AGE levels and changes in blood glucose between mid-gestation groups and late-gestation groups were compared. Factors, including AGE levels, affecting the prevalence of complications of fetal outcome in GDMs were investigated.
resultMid-gestation and late-gestation GDMs had significantly higher serum AGE levels and fasting blood glucose than their respective controls (P<0.001 and P<0.05, respectively). After treatment mid-gestation GDMs had significantly lower blood glucose levels at late gestation (P<0.05), but their serum AGE levels remained relatively high. There were no significant changes in serum AGE levels from mid- to late gestation. Women with GDM who had abnormal fetal outcomes had significantly higher maternal serum AGE levels than controls with normal fetal outcome (P<0.05). Particularly, those pregnancies that resulted in birth asphyxia, congenital malformations or stillbirth had higher serum AGEs (P<0.05). Logistic regression analysis showed elevated AGEs as a predictor of adverse perinatal outcome in GDMs, OR=6.285 (P<0.001, 95% CI 2.561 to 15.534).
conclusionHigh-serum AGE is an adverse factor in perinatal outcomes in GDMs. Sustained high AGE levels from mid- to late gestation could be an indicator of adverse perinatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.